Ovid Therapeutics
Open
$2.77
Prev. Close
$2.77
High
$2.77
Low
$2.77
Market Snapshot
$191.56M
-11.0
-0.38
$566K
23
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
emptyResult
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Recently from Cashu
Ovid Therapeutics Reports Promising Trial Results for Epilepsy Drug OV329
Ovid Therapeutics Advances Epilepsy Drug Development with Promising Study Results Ovid Therapeutics demonstrates a significant breakthrough in its pursuit of novel therapies for drug-resistant epileps…
Ovid Therapeutics: Stock Update and Recent Developments.
Please provide the content you'd like me to summarize, and I'll create a 300-word article for you.
Ovid Therapeutics Expands Clinical Trials for Innovative Epilepsy Treatment OV101
Ovid Therapeutics Expands Clinical Trials for Neurological Disorders Ovid Therapeutics, a biopharmaceutical company focused on developing innovative therapies for neurological disorders, recently anno…
Ovid Therapeutics Stock Overview: Recent Developments and Market Insights.
Sure! Please provide the text you'd like me to summarize, and I'll create a 300-word paragraph for you.